282 related articles for article (PubMed ID: 2715168)
1. Determination of the proliferative potential of human brain tumors using the monoclonal antibody Ki-67.
Deckert M; Reifenberger G; Wechsler W
J Cancer Res Clin Oncol; 1989; 115(2):179-88. PubMed ID: 2715168
[TBL] [Abstract][Full Text] [Related]
2. Ki-67 immunoreactivity in human central nervous system tumors: a study with MIB 1 monoclonal antibody on archival material.
Karamitopoulou E; Perentes E; Diamantis I; Maraziotis T
Acta Neuropathol; 1994; 87(1):47-54. PubMed ID: 7511316
[TBL] [Abstract][Full Text] [Related]
3. Microvessel density in brain tumors.
Assimakopoulou M; Sotiropoulou-Bonikou G; Maraziotis T; Papadakis N; Varakis I
Anticancer Res; 1997; 17(6D):4747-53. PubMed ID: 9494601
[TBL] [Abstract][Full Text] [Related]
4. Expression of a restrictive receptor for interleukin 13 is associated with glial transformation.
Debinski W; Slagle B; Gibo DM; Powers SK; Gillespie GY
J Neurooncol; 2000 Jun; 48(2):103-11. PubMed ID: 11083073
[TBL] [Abstract][Full Text] [Related]
5. The proliferation rate of intracranial tumors as defined by the monoclonal antibody KI 67. Application of the method to paraffin embedded specimens.
Böker DK; Stark HJ
Neurosurg Rev; 1988; 11(3-4):267-72. PubMed ID: 2855108
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical detection of dUTPase in intracranial tumors.
Romeike BF; Böckeler A; Kremmer E; Sommer P; Krick C; Grässer F
Pathol Res Pract; 2005; 201(11):727-32. PubMed ID: 16325515
[TBL] [Abstract][Full Text] [Related]
7. Expression of Ki-67, topoisomerase IIalpha and c-MYC in astrocytic tumors: correlation with the histopathological grade and proliferative status.
Faria MH; Gonçalves BP; do Patrocínio RM; de Moraes-Filho MO; Rabenhorst SH
Neuropathology; 2006 Dec; 26(6):519-27. PubMed ID: 17203587
[TBL] [Abstract][Full Text] [Related]
8. [Cellular kinetics of cerebral glioma: study of the proliferative activity using monoclonal antibody Ki 67. Apropos of 60 cases].
Parent M; Blond S; Gosset P; Lejeune JP; Lesoin F; Dhellemmes P; Jomin M; Christiaens JL; Dupont A
Arch Anat Cytol Pathol; 1990; 38(3):81-5. PubMed ID: 2363592
[TBL] [Abstract][Full Text] [Related]
9. Nogo-a expression in glial CNS tumors: a tool to differentiate between oligodendrogliomas and other gliomas?
Kuhlmann T; Gutenberg A; Schulten HJ; Paulus W; Rohde V; Bruck W
Am J Surg Pathol; 2008 Oct; 32(10):1444-53. PubMed ID: 18685489
[TBL] [Abstract][Full Text] [Related]
10. Nucleolar organizer region score and Ki-67 labelling index in high-grade gliomas and metastatic brain tumours.
Hara A; Hirayama H; Sakai N; Yamada H; Tanaka T; Mori H
Acta Neurochir (Wien); 1991; 109(1-2):37-41. PubMed ID: 1648862
[TBL] [Abstract][Full Text] [Related]
11. Ezrin immunoreactivity is associated with increasing malignancy of astrocytic tumors but is absent in oligodendrogliomas.
Geiger KD; Stoldt P; Schlote W; Derouiche A
Am J Pathol; 2000 Dec; 157(6):1785-93. PubMed ID: 11106550
[TBL] [Abstract][Full Text] [Related]
12. Identification of proliferating cells in human gliomas using the monoclonal antibody Ki-67.
Zuber P; Hamou MF; de Tribolet N
Neurosurgery; 1988 Feb; 22(2):364-8. PubMed ID: 2832782
[TBL] [Abstract][Full Text] [Related]
13. PCNA and Ki-67 in central nervous system tumors: correlation with the histological type and grade.
Kayaselçuk F; Zorludemir S; Gümürdühü D; Zeren H; Erman T
J Neurooncol; 2002 Apr; 57(2):115-21. PubMed ID: 12125971
[TBL] [Abstract][Full Text] [Related]
14. [Histological and molecular classification of gliomas].
Figarella-Branger D; Colin C; Coulibaly B; Quilichini B; Maues De Paula A; Fernandez C; Bouvier C
Rev Neurol (Paris); 2008; 164(6-7):505-15. PubMed ID: 18565348
[TBL] [Abstract][Full Text] [Related]
15. p53 protein expression in central nervous system tumors: an immunohistochemical study with CM1 polyvalent and DO-7 monoclonal antibodies.
Karamitopoulou E; Perentes E; Diamantis I
Acta Neuropathol; 1993; 85(6):611-6. PubMed ID: 8337939
[TBL] [Abstract][Full Text] [Related]
16. The relationship between Ki-67 labeling and mitotic index in gliomas and meningiomas: demonstration of the variability of the intermitotic cycle time.
Schröder R; Bien K; Kott R; Meyers I; Vössing R
Acta Neuropathol; 1991; 82(5):389-94. PubMed ID: 1767633
[TBL] [Abstract][Full Text] [Related]
17. Flow-through fluorocytophotometry of different brain tumours.
Lehmann J; Krug H
Acta Neuropathol; 1980; 49(2):123-32. PubMed ID: 7355677
[TBL] [Abstract][Full Text] [Related]
18. Ki-67 immunoperoxidase stain as marker for the histological grading of nervous system tumours.
Shibata T; Burger PC; Kleihues P
Acta Neurochir Suppl (Wien); 1988; 43():103-6. PubMed ID: 2463741
[TBL] [Abstract][Full Text] [Related]
19. Expression of vascular endothelial growth factor and its receptors in the anaplastic progression of astrocytoma, oligodendroglioma, and ependymoma.
Chan AS; Leung SY; Wong MP; Yuen ST; Cheung N; Fan YW; Chung LP
Am J Surg Pathol; 1998 Jul; 22(7):816-26. PubMed ID: 9669344
[TBL] [Abstract][Full Text] [Related]
20. [Histological classification of human gliomas: state of art and controversies].
Figarella-Branger D; Bouvier C
Bull Cancer; 2005 Apr; 92(4):301-9. PubMed ID: 15888386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
